Shopping Cart
Remove All
Your shopping cart is currently empty
SR-29065 is a selective REV-ERBα agonist that inhibits BMAL1 transcription within the circadian transcription–translation feedback loop, and it has been applied to evaluate whether targeting both negative regulatory limbs of circadian control yields synergistic anti-tumor effects in glioblastoma models, supporting its broader use in autoimmune disorder and circadian rhythm research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $1,350 | - | In Stock | |
| 5 mg | $2,970 | - | In Stock | |
| 10 mg | $4,460 | - | In Stock | |
| 25 mg | $6,620 | - | In Stock | |
| 50 mg | $8,930 | - | In Stock |
| Description | SR-29065 is a selective REV-ERBα agonist that inhibits BMAL1 transcription within the circadian transcription–translation feedback loop, and it has been applied to evaluate whether targeting both negative regulatory limbs of circadian control yields synergistic anti-tumor effects in glioblastoma models, supporting its broader use in autoimmune disorder and circadian rhythm research. |
| Targets&IC50 | NR1D1:0.11 µM |
| In vitro | Method: Structure–activity relationship optimization of REV-ERBα-selective ligands was conducted, followed by in vivo evaluation in a mouse experimental autoimmune encephalomyelitis (EAE) model. Result:SR-29065 reduced the frequency and number of T cells in the CNS and modulated REV-ERB target gene expression in mice, indicating effective in vivo target engagement[1]. |
| Synonyms | SR-29065, SR29065, SR 29065 |
| Molecular Weight | 518.52 |
| Formula | C24H24F6N2O2S |
| Cas No. | 2756883-91-5 |
| Smiles | CC(C)CN1C=C(C2=C1C=C(C=C2)C3=CC=CC=C3C(F)(F)F)C(C(F)(F)F)NS(=O)(=O)C4CC4 |
| Color | Yellow |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.